Brief: Aligos Therapeutics Initiates Dosing With Its Small Interfering RNA Drug Candidate, ALG-125755, In Subjects With Chronic Hepatitis B
14/12/2022 21:12
Dec 14 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS INITIATES DOSING WITH ITS SMALL
INTERFERING
RNA (SIRNA) DRUG CANDIDATE, ALG-125755, IN SUBJECTS WITH CHRONIC
HEPATITIS B (CHB)
Source text for Eikon: ID:nGNX5cCq81
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue